Multimorbidity and use of hypnotic and anxiolytic drugs: cross-sectional and follow-up study in primary healthcare in Iceland.
The prevalence of multimorbidity is increasing worldwide, presumably leading to an increased use of medicines. During the last decades the use of hypnotic and anxiolytic benzodiazepine derivatives and related drugs has increased dramatically. These drugs are frequently prescribed for people with a sleep disorder often merely designated as "insomnia" in the medical records and lacking a clear connection with the roots of the patients' problems. Our aim was to analyse the prevalence of multimorbidity in primary healthcare in Iceland, while concurrently investigating a possible association with the prevalence and incidence of hypnotic/anxiolytic prescriptions, short-term versus chronic use.



Data were retrieved from a comprehensive database of medical records from primary healthcare in Iceland to find multimorbid patients and prescriptions for hypnotics and anxiolytics, linking diagnoses (ICD-10) and prescriptions (2009-2012) to examine a possible association. Nearly 222,000 patients, 83 % being local residents in the capital area, who contacted 16 healthcare centres served in total by 140 general practitioners, were set as a reference to find the prevalence of multimorbidity as well as the prevalence and incidence of hypnotic/anxiolytic prescriptions.



The prevalence of multimorbidity in the primary care population was 35 %, lowest in the young, increasing with age up to the 80+ group where it dropped somewhat. The prevalence of hypnotic/anxiolytic prescriptions was 13.9 %. The incidence rate was 19.4 per 1000 persons per year in 2011, and 85 % of the patients prescribed hypnotics/anxiolytics were multimorbid. Compared to patients without multimorbidity, multimorbid patients were far more likely to be prescribed a hypnotic and/or an anxiolytic, OR = 14.9 (95 % CI = 14.4-15.4).



Patients with multiple chronic conditions are common in the primary care setting, and prevalence and incidence of hypnotic/anxiolytic prescriptions are high. Solely explaining use of these drugs by linear thinking, i.e. that "insomnia" leads to their prescription is probably simplistic, since the majority of patients prescribed these drugs are multimorbid having several chronic conditions which could lead to sleeping problems. However, multimorbidity as such is not an indication for hypnotics, and doctors should be urged to greater caution in their prescribing, bearing in mind non-pharmacological therapy options.
Centre of Development, Primary Health Care of the Capital Area, Reykjavik, Iceland. kristjan.linnet@heilsugaeslan.is.
Kristjan
0000-0002-0189-9519
K
Linnet
Clinical Quality and Services, Directorate of Health, Reykjavik, Iceland.|Faculty of Pharmaceutical Sciences, School of Health Sciences, University of Iceland, Reykjavik, Iceland.|Centre of Public Health Sciences, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Larus S
LS
Gudmundsson
Department of Family Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Frida G
FG
Birgisdottir
Centre of Development, Primary Health Care of the Capital Area, Reykjavik, Iceland.|Department of Family Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Emil L
EL
Sigurdsson
Clinical Quality and Services, Directorate of Health, Reykjavik, Iceland.|Department of Pharmacology and Toxicology, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Magnus
M
Johannsson
Centre of Development, Primary Health Care of the Capital Area, Reykjavik, Iceland.|Department of Family Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.|Faculty of Medicine, Department of Public Health and General Practice Research Unit, Norwegian University of Science and Technology, Trondheim, Norway.
Margret O
MO
Tomasdottir
Centre of Development, Primary Health Care of the Capital Area, Reykjavik, Iceland.|Department of Family Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.|Faculty of Medicine, Department of Public Health and General Practice Research Unit, Norwegian University of Science and Technology, Trondheim, Norway.
Johann A
JA
Sigurdsson
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease / Q000453:epidemiology*; D015897:Comorbidity; D003430:Cross-Sectional Studies; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D007055:Iceland / Q000453:epidemiology; D015994:Incidence; D007223:Infant; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011320:Primary Health Care / Q000706:statistics & numerical data*; D012737:Sex Factors; D007319:Sleep Initiation and Maintenance Disorders / Q000453:epidemiology*; D055815:Young Adult
D014151:Anti-Anxiety Agents; D006993:Hypnotics and Sedatives
Anxiolytics; Chronic health problems; Hypnotics; ICD-10; Insomnia; Multimorbidity; Multiple chronic conditions; Primary care